Page 126 - medicina-integrativa_compress

116 PARTE II, SECCIÓN 1 TRASTORNOS AFECTIVOS

23. Arcos-Burgos M, Castellanos FX, Konecki D, et al: Pedigree 47. MTA Cooperative Group, National Institute of Mental Health
disequilibrium test (PDT) replicates association and linkage between Multimodal Treatment Study of ADHD Follow-up: 24-month
DRD 4 and ADHD in multigenerational and extended pedigrees from outcomes of treatment strategies for attention-deficit/hyperactivity
a genetic isolate. Mol Psychiatry 9:252-259, 2004. disorder. Pediatrics 113:754-761, 2004.
24. Abdolmaleky HM, Smith CL, Faraone SV, et al: Methylomics in 48. MTA Cooperative Group, National Institute of Mental Health
psychiatry: Modulation of gene-environment interactions may be Multimodal Treatment Study of ADHD Follow-up: Changes in
through DNA methylation. Am J Med Genet B Neuropsychiatr effectiveness and growth after the end of treatment. Pediatrics
Genet 127:51-59, 2004. 113:762-769, 2004.
25. Cook DE, Kestenbaum C, Honaker LM, Anderson ER: Joint 49. Cohen MW: The Attention Zone: A Parents’ Guide to Attention
statement on the impact of entertainment violence on children: Deficit/Hyperactivity Disorder. New York, Bruner Mazel, 1998.
Congressional Public Health Summit, July 26, 2000. 50. McCabe SE, Teter CJ, Boyd CJ: The use, misuse, and diversion of
www.AAP.org/advocacy/releases. prescription stimulants among middle and high school students.
26. AAP Policy Statement. Media violence (RE9526). Pediatrics 95: Subst Use Misuse 39:1095-1116, 2004.
949-951, 1995. 51. McCabe SE, Knight JR, Teter CJ, Weschler H: Nonmedical use of
27. Elkind D: The Hurried Child: Growing Up Too Fast Too Soon, 3rd prescription stimulants among U.S. college students. Addiction
ed. Cambridge, MA, Perseus, 2001. 99:96-106, 2005.
28. Biederman J, Milberger S, Faraone S, et al: Family-environmental 52. Michelson D, Allen AJ, Busner J, et al: Once-daily atomoxetine
risk factors for ADHD: A test of Rutter’s indicators of adversity. treatment for children and adolescents with attention deficit
Arch Gen Psychiatry 49:464-470, 1995. hyperactivity disorder: A randomized placebo-controlled study.
29. Brazelton TB: Fetal observations: Could they relate to another Am J Psychiatry 159:1896-1901, 2002.
modality, such as touch? In Field TM (ed): Touch in Early 53. Atomoxetine (Strattera) revisited. Med Lett Drug Ther 46:65, 2004.
Development. Mahwah, NJ, Lawrence Erlbaum, 1995, pp 53-65. 54. Chan E, Gardiner P, Kemper KJ. At least it’s natural: Herbs and
30. Gunnar MR, Connors J, Isensee J, Wall L: Adrenocortical activity dietary supplements in ADHD. Contemp Pediatr 17:116-130, 2000.
and behavioral distress in newborns. Dev Psychobiol 21:279- 55. Cala S, Crismon ML, Baumgartner J: A survey of herbal use in
310, 1988. children with attention-deficit-hyperactivity disorder or depression.
31. Meaney MJ, Aitken D: Neonatal handling and the development of Pharmacotherapy 23:222-230, 2003.
the adrenocortical response. In Gunzenhauser N (ed): Advances in 56. Smits M, Nagtegaal E, Valentijn S, et al: Melatonin for chronic sleep
Touch: New Implications in Human Development. Skillman, onset insomnia in children with attention deficit hyperactivity
NJ, Johnson & Johnson, 1990, pp 80-89. disorder: Randomized placebo-controlled trial. J Neurol Neurosurg
32. Teicher MH, Andersen SL, Polcari A et al: The neurobiological Psychiatry 67:840, 1999.
consequences of early stress and childhood maltreatment. 57. Tjon Pian Gi CV, Broeren JPA, Starreveld JS, Versteegh FGA:
Neurosci Biobehav Rev 27:33-44, 2003. Melatonin for treatment of sleeping disorders in children with
33. Polluting Our Future: Chemical pollution in the U.S. that affects attention deficit/hyperactivity disorder: A preliminary open-label
child development and learning. National Environmental Trust study. Eur J Pediatr 162:554-555, 2003.
(NET), Physicians for Social Responsibility (PSR) and Learning 58. Sheldon SH: Proconvulsant effects of oral melatonin in
Disabilities Association of America (LDA), September 2000. neurologically disabled children [Letter]. Lancet 351:1254, 1998.
34. http://www.nationalchildrensstudy.gov. 59. Wheatley D: Medicinal plants for insomnia: A review of their
35. ACQIP: Monitoring Children with Attention Deficit Hyperactivity pharmacology, efficacy, and tolerability. J Psychopharmocol 19:
Disorder. Ambulatory Care Quality Improvement Program. 414-421, 2005.
Elk Grove, IL, American Academy of Pediatrics, 1997. 60. Donath F, Quispe BS, Diefenbach I, et al: Critical evaluation of the
36. Bennett FC: Stimulant medication for the child with attention deficit administration of valerian extract on sleep structure and sleep
hyperactivity disorder. Pediatr Clin North Am 6:929, 1999. quality. Pharmacopsychiatry 35:47-53, 2000.
37. Greenhill LL: Stimulant medication treatment of children with 61. Oken BS, Storzbach DM, Kaye JA: The efficacy of Ginkgo biloba
attention deficit hyperactivity disorder. In Jensen PS, Cooper JR on cognitive function in Alzheimer disease. Arch Neurol 55:
(eds): Attention Deficit Hyperactivity Disorder: State of the 1409, 1998.
Sciences, Best Practices. Kingston, NJ, Civic Research Institute, 62. Rohdewald P: A review of the French maritime pine bark extract
2002, pp 9-14. (Pycnogenol), a herbal medication with a diverse clinical
38. Greenhill LL: Clinical effects of stimulant medication in ADHD. In pharmacology. Int J Clin Pharmacol Ther 40:158-168, 2002.
Solanto MV, Arnsten AF, Castellanos FX (eds): Stimulant Drugs and 63. Masami K: Pycnogenol’s therapeutic effect in improving ADHD
ADHD: Basic and Clinical Neuroscience. New York, Oxford symptoms in children confirmed. Mainichi Shimbun 10:21, 2000.
University Press, 2001, pp 31-71. 64. Marlier L, Gaugler C, Messer J: Olfactory stimulation prevents apnea
39. Shaywitz SS, Shaywitz BA: Attention deficit disorder: Diagnosis and in premature newborns. Pediatrics 115:83-88, 2005.
role of Ritalin in management. In Greenhill LL, Osman BB (eds): 65. Diego MA, Jones NA, Field T, et al: Aromatherapy positively affects
Ritalin: Theory and Patient Management. New York, Mary Ann mood, EEG patterns of alertness, and math computations.
Liebert, 1991, pp 45-67. Int J Neurosci 96:217-224, 1998.
40. Adesman AR, Morgan AM: Management of stimulant medication in 66. Schultz V, Hansel R, Tyler VE: Rational Phytotherapy. New York,
children with attention deficit/hyperactivity disorder. Pediatr Clin Springer-Verlag, 2000.
North Am 6:945, 1999. 67. Varley CK: Diet and the behavior of children with attention deficit
41. Wilens T, McBurnett K, Stein M, et al: ADHD treatment with once- disorder. J Am Acad Child Psychiatry 23:182-185, 1984.
daily OROS methylphenidate: Final results from a long-term 68. Breakey J: The role of diet and behavior in childhood. J Paediatr
open-label study. J Am Acad Adolesc Psychiatry 44:1015-1023, 2005. Child Health 33:190-194, 1997.
42. Wilens TE: Straight Talk about Psychiatric Medication for Kids. New 69. Schnoll R, Burshteyn D, Cea-Aravena J: Nutrition in the treatment
York, Guilford Press, 1999, pp 191-205. of attention-deficit hyperactivity disorder: A neglected but
43. A 14-month randomized clinical trial of treatment strategies for important aspect. Appl Psychophysiol Biofeedback 28:63-75, 2003.
attention-deficit/hyperactivity disorder. The MTA Cooperative 70. American Academy of Pediatrics, Committee on Nutrition:
Group. Multimodal Treatment Study of Children with ADHD. Arch Megavitamin therapy for childhood psychoses and learning
Gen Psychiatry 56:1073-1086, 1999. disabilities. Pediatrics 58:910-912, 1976.
44. Swanson JM, Kraemer HC, Hinshaw SP, et al: Clinical relevance of 71. National Advisory Committee on Hyperkinesis and Food Additives:
the primary findings of the MTA: Success rates based on the severity Final Report to the Nutrition Foundation. New York, Nutrition
of ADHD and ODD symptoms at the end of treatment. J Am Acad Foundation, 1980.
Child Adolesc Psychiatry 40:168, 2001. 72. Harding KL, Judah RD, Gant CE: Outcome-based comparison of
45. Pelham WE Jr: Implications of the MTA Study for behavioral and Ritalin versus food-supplement treated children with AD/HD.
combined treatments. ADHD Rep 8:4, 2000. Altern Med Rev 8:319-330, 2003.
46. Jensen PS, Hinshaw SP, Kraemer HC, et al: ADHD comorbidity 73. Conners CK, Goyette CH, Southwick DS, et al: Food additives and
findings from the MTA study: Comparing comorbid subgroups. hyperkinesis: A controlled double-blind experiment. Pediatrics
J Am Acad Child Adolesc Psychiatry 40:147, 2001. 58:154-166, 1976.